Pharmacia Ab

Pfizer Health Ab

Martin Wikberg

Anders Ringberg

Birgitta Olsson

Lisbeth Nilvebrant

Torkel Gren

Ulla Hoeck

Helle Kristensen

Lene Orup Jacobsen

Randy J Wald

Bengt Hall&eacute;n

Jan Str&ouml;mbom

Torkek Gren

Bo Kreilg&aring;rd

Jan Strombom

Bengt Hallen

Bo Kreilgård

Bengt Hallén

Jan Strömbom

A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.

Controlled release bead, a method of producing the same and multiple unit formulation comprising it

The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.

Therapeutic formulation for administering tolterodine with controlled release

The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.

Pharmaceutical formulation and its use

Growing community of inventors

Kullavik, Sweden

Martin Wikberg